Michelle A Kelliher

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2017621/publications.pdf

Version: 2024-02-01

101543 149698 9,101 61 36 citations h-index papers

g-index 61 61 61 13273 docs citations times ranked citing authors all docs

56

#	Article	IF	Citations
1	Therapeutic targeting of LCK tyrosine kinase and mTOR signaling in T-cell acute lymphoblastic leukemia. Blood, 2022, 140, 1891-1906.	1.4	19
2	Prostaglandin E2 stimulates cAMP signaling and resensitizes human leukemia cells to glucocorticoid-induced cell death. Blood, 2021, 137, 500-512.	1.4	9
3	T cell–derived tumor necrosis factor induces cytotoxicity by activating RIPK1-dependent target cell death. JCI Insight, 2021, 6, .	5.0	7
4	RIPK1 Mediates TNF-Induced Intestinal Crypt Apoptosis During Chronic NF-κB Activation. Cellular and Molecular Gastroenterology and Hepatology, 2020, 9, 295-312.	4.5	26
5	Ptpn6 inhibits caspase-8- and Ripk3/Mlkl-dependent inflammation. Nature Immunology, 2020, 21, 54-64.	14.5	33
6	Sequential activation of necroptosis and apoptosis cooperates to mediate vascular and neural pathology in stroke. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 4959-4970.	7.1	98
7	ESRRB regulates glucocorticoid gene expression in mice and patients with acute lymphoblastic leukemia. Blood Advances, 2020, 4, 3154-3168.	5.2	3
8	BID-ding on necroptosis in MDS. Blood, 2019, 133, 103-104.	1.4	1
9	NOTCH1 Represses MCL-1 Levels in GSI-resistant T-ALL, Making them Susceptible to ABT-263. Clinical Cancer Research, 2019, 25, 312-324.	7.0	11
10	Dendritic Cell RIPK1 Maintains Immune Homeostasis by Preventing Inflammation and Autoimmunity. Journal of Immunology, 2018, 200, 737-748.	0.8	30
11	NOTCH Signaling in T-Cell-Mediated Anti-Tumor Immunity and T-Cell-Based Immunotherapies. Frontiers in Immunology, 2018, 9, 1718.	4.8	47
12	Pathogen blockade of TAK1 triggers caspase-8–dependent cleavage of gasdermin D and cell death. Science, 2018, 362, 1064-1069.	12.6	639
13	Elevated A20 promotes TNF-induced and RIPK1-dependent intestinal epithelial cell death. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, E9192-E9200.	7.1	66
14	The pseudokinase MLKL activates PAD4-dependent NET formation in necroptotic neutrophils. Science Signaling, 2018, 11, .	3.6	65
15	Oncogenic hijacking of the stress response machinery in T cell acute lymphoblastic leukemia. Nature Medicine, 2018, 24, 1157-1166.	30.7	63
16	ATACseqQC: a Bioconductor package for post-alignment quality assessment of ATAC-seq data. BMC Genomics, 2018, 19, 169.	2.8	153
17	Analyzing Necroptosis Using an RIPK1 Kinase Inactive Mouse Model of TNF Shock. Methods in Molecular Biology, 2018, 1857, 125-134.	0.9	1
18	Connecting immune deficiency and inflammation. Science, 2018, 361, 756-757.	12.6	5

#	Article	IF	Citations
19	Kinase Activities of RIPK1 and RIPK3 Can Direct IFN- \hat{l}^2 Synthesis Induced by Lipopolysaccharide. Journal of Immunology, 2017, 198, 4435-4447.	0.8	51
20	CK2 inhibitor CX-4945 destabilizes NOTCH1 and synergizes with JQ1 against human T-acute lymphoblastic leukemic cells. Haematologica, 2017, 102, e17-e21.	3.5	15
21	RIPK1 mediates a disease-associated microglial response in Alzheimer's disease. Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, E8788-E8797.	7.1	265
22	RUNX1 is required for oncogenic Myb and Myc enhancer activity in T-cell acute lymphoblastic leukemia. Blood, 2017, 130, 1722-1733.	1.4	64
23	BET Bromodomain Proteins Function as Master Transcription Elongation Factors Independent of CDK9 Recruitment. Molecular Cell, 2017, 67, 5-18.e19.	9.7	347
24	RIPK1 and RIPK3 Kinases Promote Cell-Death-Independent Inflammation by Toll-like Receptor 4. Immunity, 2016, 45, 46-59.	14.3	228
25	Phosphorylation of the Mdm2 oncoprotein by the c-Abl tyrosine kinase regulates p53 tumor suppression and the radiosensitivity of mice. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, 15024-15029.	7.1	7
26	The Public Repository of Xenografts Enables Discovery and Randomized Phase II-like Trials in Mice. Cancer Cell, 2016, 29, 574-586.	16.8	227
27	High-Throughput Screening of Tyrosine Kinase Inhibitor Resistant Genes in CML. Methods in Molecular Biology, 2016, 1465, 159-173.	0.9	4
28	Mdm2 Phosphorylation Regulates Its Stability and Has Contrasting Effects on Oncogene and Radiation-Induced Tumorigenesis. Cell Reports, 2016, 16, 2618-2629.	6.4	24
29	CYLD Proteolysis Protects Macrophages from TNF-Mediated Auto-necroptosis Induced by LPS and Licensed by Type I IFN. Cell Reports, 2016, 15, 2449-2461.	6.4	83
30	RIPK1 mediates axonal degeneration by promoting inflammation and necroptosis in ALS. Science, 2016, 353, 603-608.	12.6	448
31	NEMO Prevents RIP Kinase 1-Mediated Epithelial Cell Death and Chronic Intestinal Inflammation by NF-κB-Dependent and -Independent Functions. Immunity, 2016, 44, 553-567.	14.3	157
32	Identifying Mechanisms of Glucocorticoid Resistance in Relapsed Pediatric T-ALL. Blood, 2016, 128, 2769-2769.	1.4	1
33	IFN \hat{I}^3 -Induced Necroptosis Contributes to Hematopoietic Stem and Progenitor Cell Death and Bone Marrow Failure. Blood, 2016, 128, 1485-1485.	1.4	0
34	JAK/STAT Pathway Inhibition Reverts IL7-Induced Glucocorticoid Resistance in a Subset of Human T-Cell Acute Lymphoblastic Leukemia. Blood, 2016, 128, 3963-3963.	1.4	0
35	NEMO Prevents Steatohepatitis and Hepatocellular Carcinoma by Inhibiting RIPK1 Kinase Activity-Mediated Hepatocyte Apoptosis. Cancer Cell, 2015, 28, 582-598.	16.8	98
36	c-Myc inhibition prevents leukemia initiation in mice and impairs the growth of relapsed and induction failure pediatric T-ALL cells. Blood, 2014, 123, 1040-1050.	1.4	129

#	Article	IF	CITATIONS
37	An epigenetic mechanism of resistance to targeted therapy in T cell acute lymphoblastic leukemia. Nature Genetics, 2014, 46, 364-370.	21.4	333
38	RIPK1 Blocks Early Postnatal Lethality Mediated by Caspase-8 and RIPK3. Cell, 2014, 157, 1189-1202.	28.9	452
39	Hematopoietic RIPK1 deficiency results in bone marrow failure caused by apoptosis and RIPK3-mediated necroptosis. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, 14436-14441.	7.1	83
40	Maturation Stage of T-cell Acute Lymphoblastic Leukemia Determines BCL-2 versus BCL-XL Dependence and Sensitivity to ABT-199. Cancer Discovery, 2014, 4, 1074-1087.	9.4	201
41	Caspase-8 and RIP kinases regulate bacteria-induced innate immune responses and cell death. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, 7391-7396.	7.1	250
42	RNA G-quadruplexes cause eIF4A-dependent oncogene translation in cancer. Nature, 2014, 513, 65-70.	27.8	506
43	Cutting Edge: RIPK1 Kinase Inactive Mice Are Viable and Protected from TNF-Induced Necroptosis In Vivo. Journal of Immunology, 2014, 193, 1539-1543.	0.8	256
44	RIPK1 maintains epithelial homeostasis by inhibiting apoptosis and necroptosis. Nature, 2014, 513, 90-94.	27.8	439
45	Leukemia Propagating Cells Akt Up. Cancer Cell, 2014, 25, 263-265.	16.8	2
46	Abstract PR02: Targeting NOTCH1 and C-MYC in humanized models of relapsed and induction failure pediatric T-ALL. , 2014, , .		0
47	Ripk-Mediated Necroptosis Induces Inflammation and Bone Marrow Failure in Mice. Blood, 2014, 124, 1599-1599.	1.4	0
48	RIP1-driven autoinflammation targets IL-1 \hat{l} ± independently of inflammasomes and RIP3. Nature, 2013, 498, 224-227.	27.8	149
49	Core Transcriptional Regulatory Circuit Controlled by the TAL1 Complex in Human T Cell Acute Lymphoblastic Leukemia. Cancer Cell, 2012, 22, 209-221.	16.8	262
50	TYK2-STAT1 Pathway Positively Regulates BCL2 Gene Expression in T-Cell Acute Lymphoblastic Leukemia. Blood, 2012, 120, 1470-1470.	1.4	1
51	Notch1 inhibition targets the leukemia-initiating cells in a Tal1/Lmo2 mouse model of T-ALL. Blood, 2011, 118, 1579-1590.	1.4	89
52	Deletion-Based Mechanisms of Notch1 Activation In T-ALL: Key Roles for RAG Recombinase and A Conserved Internal Translational Start Site In Notch1 Blood, 2010, 116, 3367-3367.	1.4	5
53	NOD2, RIP2 and IRF5 Play a Critical Role in the Type I Interferon Response to Mycobacterium tuberculosis. PLoS Pathogens, 2009, 5, e1000500.	4.7	239
54	Notch1 Contributes to Mouse T-Cell Leukemia by Directly Inducing the Expression of c -myc. Molecular and Cellular Biology, 2006, 26, 8022-8031.	2.3	241

#	Article	IF	CITATIONS
55	Tall and a DNA Binding Mutant (TallR188G;R189G) Cooperate with LMO2 To Induce Leukemia in Mice Blood, 2006, 108, 1414-1414.	1.4	O
56	Rip1 Mediates the Trif-dependent Toll-like Receptor 3- and 4-induced NF-κB Activation but Does Not Contribute to Interferon Regulatory Factor 3 Activation. Journal of Biological Chemistry, 2005, 280, 36560-36566.	3.4	273
57	Activating Notch1 Mutations in Mouse Models of T-ALL Blood, 2005, 106, 2609-2609.	1.4	2
58	RIP Links TLR4 to Akt and Is Essential for Cell Survival in Response to LPS Stimulation. Journal of Experimental Medicine, 2004, 200, 399-404.	8.5	69
59	RIP1 is an essential mediator of Toll-like receptor 3–induced NF-κB activation. Nature Immunology, 2004, 5, 503-507.	14.5	744
60	The DNA binding activity of TAL-1 is not required to induce leukemia/lymphoma in mice. Oncogene, 2001, 20, 3897-3905.	5.9	55
61	The Death Domain Kinase RIP Mediates the TNF-Induced NF-κB Signal. Immunity, 1998, 8, 297-303.	14.3	1,026